Neomorphic mutations create therapeutic challenges in cancer. (Q39007820)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27841866%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

review article

4 references

6 November 2020

20 December 2020

8 February 2021

Neomorphic mutations create therapeutic challenges in cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27841866%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

1 reference

6 November 2020

1 reference

20 December 2020

1 reference

8 February 2021

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27841866%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Gordon B. Mills

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27841866%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Lydia W T Cheung

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27841866%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

author name string

V Takiar

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27841866%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

M Gao

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27841866%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

language of work or name

English

0 references

publication date

14 November 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27841866%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

23 March 2017

3 references

6 November 2020

20 December 2020

8 February 2021

4 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27841866%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

6 November 2020

20 December 2020

8 February 2021

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27841866%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

page(s)

1607-1618

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27841866%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27841866%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2016.312

27 March 2020

exact match

0 references

cites work

Isocitrate dehydrogenase and related oxidative decarboxylases

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Control of mitochondrial redox balance and cellular defense against oxidative damage by mitochondrial NADP+-dependent isocitrate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

FeII/alpha-ketoglutarate-dependent hydroxylases and related enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Prolyl hydroxylases as regulators of cell metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

IDH mutation impairs histone demethylation and results in a block to cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Novel Scaffolds of Cell-Active Histone Demethylase Inhibitors Identified from High-Throughput Screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Pan-cancer patterns of somatic copy number alteration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Mutational landscape and significance across 12 major cancer types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

PIK3CA is implicated as an oncogene in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Cancer-specific mutations in PIK3CA are oncogenic in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Integrated genomic characterization of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

The somatic genomic landscape of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Comprehensive molecular characterization of human colon and rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Somatic mutations of PIK3R1 promote gliomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Intermolecular interactions of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

PTEN: life as a tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Protein phosphatase activity of PTEN inhibited the invasion of glioma cells with epidermal growth factor receptor mutation type III expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Ubiquitination regulates PTEN nuclear import and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Nuclear PTEN tumor-suppressor functions through maintaining heterochromatin structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Phosphorylation of the PTEN tail regulates protein stability and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Discovery and functional characterization of a neomorphic PTEN mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

PI(3,4,5)P3 and PI(3,4)P2 levels correlate with PKB/akt phosphorylation at Thr308 and Ser473, respectively; PI(3,4)P2 levels determine PKB activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

PTEN-deficient cancers depend on PIK3CB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

21 January 2018

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

T antigen is bound to a host protein in SY40-transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Participation of p53 cellular tumour antigen in transformation of normal embryonic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

The first 30 years of p53: growing ever more complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Wild-type p53 can inhibit oncogene-mediated focus formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

The p53 proto-oncogene can act as a suppressor of transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Mutant p53: one name, many proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Live or let die: the cell's response to p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Blinded by the Light: The Growing Complexity of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Transcriptional control of human p53-regulated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

How many mutant p53 molecules are needed to inactivate a tetramer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Gain of function mutations in p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

p53 and p73 display common and distinct requirements for sequence specific binding to DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Structural evolution of p53, p63, and p73: Implication for heterotetramer formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Physical interaction with Yes-associated protein enhances p73 transcriptional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Mutant p53 drives invasion by promoting integrin recycling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

hMre11 and hRad50 nuclear foci are induced during the normal cellular response to DNA double-strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Mechanisms of mutant p53 stabilization in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Drugging the HDAC6-HSP90 interplay in malignant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Reactivation of mutant p53: molecular mechanisms and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Allele-specific p53 mutant reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Muscle-specific transcriptional activation by MyoD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

MyoD and the regulation of myogenesis by helix-loop-helix proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

A point mutation in the MyoD basic domain imparts c-Myc-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

MyoD1: a nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

FOXO1-FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

The involvement of the transcription factor Yin Yang 1 in cancer development and progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Transcription factor YY1: structure, function, and therapeutic implications in cancer biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Yin Yang 1 regulates the transcriptional activity of androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Yin yang 1 modulates taxane response in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Expression of transcription factor Yin Yang 1 in human osteosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Yin Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B-cell transformation and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Yin-yang 1 activates the c-myc promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

YY1 and c-Myc associate in vivo in a manner that depends on c-Myc levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Yin Yang 1 is a negative regulator of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

YY1 binding to a subset of p53 DNA-target sites regulates p53-dependent transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Neomorphic effects of recurrent somatic mutations in Yin Yang 1 in insulin-producing adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Kinome-wide decoding of network-attacking mutations rewiring cancer signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Unmasking determinants of specificity in the human kinome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Regulation of singlet oxygen-induced apoptosis by cytosolic NADP+-dependent isocitrate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Regulation of the PI3K pathway through a p85α monomer-homodimer equilibrium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

When mutants gain new powers: news from the mutant p53 field.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

p73 function is inhibited by tumor-derived p53 mutants in mammalian cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Chemosensitivity linked to p73 function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.312

Infectious disease: Glutamine analogue reverses cerebral malaria

31 March 2020

1 reference

12 December 2020

Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma

1 reference

12 December 2020

Phosphatidylinositol 3'-kinase is activated by association with IRS-1 during insulin stimulation

1 reference

12 December 2020

Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes

1 reference

12 December 2020

p63 and p73: roles in development and tumor formation

1 reference

12 December 2020

Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation

1 reference

12 December 2020

Expression of transcription factor Yin Yang 1 in prostate cancer

1 reference

12 December 2020

Overexpression of VEGF and TGF-beta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection

1 reference

12 December 2020

Identifiers

DOI

10.1038/ONC.2016.312

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27841866%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27841866%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

1 reference